



September 28, 2023

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Chief Strategy Officer
Toshiya Kitagawa
(TEL. 03-6214-3600)

GNI Group's New Management Structure

GNI Group Co., Ltd. ("GNI"; "we", "the Group", including our subsidiaries and affiliates) today announced that our Board of Directors has resolved at a meeting on September 28, 2023 to change the responsibilities of directors and executive officers effective October 1, 2023.,

1. Change of the responsibilities of directors and executive officers

Name	New Roles	Existing Roles
Kan-ichiro Suzuki	Director, Executive Officer, Vice President	Director, Executive Officer, CFO (Chief Financial Officer)
Toshiya Kitagawa	Executive Officer, CFO (Chief Financial Officer)	Executive Officer, CSO (Chief Strategy Officer)

2. Background and Reason behind the Management Structure Change

In recent years, our group has accelerated the expansion of our business in Japan, the United States, and China in both our pharmaceutical and medical device businesses. Along with this, the functions required of Japanese headquarters are becoming more sophisticated and diverse. We have decided to make the above changes in order to establish a system that allows our headquarters to respond more flexibly to the future development of our group's business.

With this organizational change, Kan-ichiro Suzuki, as Vice President, will oversee the strategy execution of the entire group from a broader perspective, while Toshiya Kitagawa will be responsible for overall financial and management

strategies, focusing on the Japanese headquarter.

About GNI Group Ltd.:

The Company is a holding company of global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below:

<https://www.gnipharma.com/>

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (“the Company”). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.